The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10595 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis

September 29, 2020 - 13:30 -- Open Access
Author(s): 
Weiss DJ, Bertozzi-Villa A, Peter W Gething, et al.
Reference: 
Lancet Infect Dis. 2020 Sep 21:S1473-3099(20)30700-3

Substantial progress has been made in reducing the burden of malaria in Africa since 2000, but those gains could be jeopardised if the COVID-19 pandemic affects the availability of key malaria control interventions. The aim of this study was to evaluate plausible effects on malaria incidence and mortality under different levels of disruption to malaria control.

COVID-19 in malaria-endemic regions: potential consequences for malaria intervention coverage, morbidity, and mortality

September 29, 2020 - 13:28 -- Open Access
Author(s): 
Teboh-Ewungkem MI, Ngwa GA
Reference: 
Lancet Infect Dis. 2020 Sep 21:S1473-3099(20)30763-5

COVID-19 has had a massive impact on the populations and economies of the world. As of Sept 9, 2020, the virus has infected more than 27 million people in 216 countries and territories worldwide, and the number of deaths is approaching a million.

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives

September 24, 2020 - 14:05 -- Open Access
Author(s): 
Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD
Reference: 
Acta Pharmacol Sin. 2020 Sep 23

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients.

Chloroquine against malaria, cancers and viral diseases

September 23, 2020 - 08:44 -- Open Access
Author(s): 
Zhou W, Wang H, Yang Y, Chen ZS, Zou C, Zhang J
Reference: 
Drug Discov Today. 2020 Sep 16:S1359-6446(20)30367-6

Quinoline (QN) derivatives are often used for the prophylaxis and treatment of malaria. Chloroquine (CQ), a protonated, weakly basic drug, exerts its antimalarial effect mainly by increasing pH and accumulating in the food vacuole of the parasites.

Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19

September 15, 2020 - 14:44 -- Open Access
Author(s): 
Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, Ke Z, Zou C, Chen ZS
Reference: 
Pharmacol Ther. 2020 Sep 7:107672

Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases.

Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19

September 15, 2020 - 14:37 -- Open Access
Author(s): 
Kang Y, Wang H, Chen H, Wang B, Yang Y, Zhao X, Ran Q, Wei J
Reference: 
Int Heart J. 2020 Sep 12

An 84-year-old woman with hypertension, Alzheimer's disease, and chronic kidney disease presented with fever and was diagnosed with corona virus disease 2019 (COVID-19).

Malaria and COVID-19: Common and Different Findings

September 10, 2020 - 08:37 -- Open Access
Author(s): 
Di Gennaro F, Marotta C, Locantore P, Pizzol D, Putoto G
Reference: 
Trop Med Infect Dis. 2020 Sep 6;5(3):E141

Malaria and COVID-19 may have similar aspects and seem to have a strong potential for mutual influence. They have already caused millions of deaths, and the regions where malaria is endemic are at risk of further suffering from the consequences of COVID-19 due to mutual side effects, such as less access to treatment for patients with malaria due to the fear of access to healthcare centers leading to diagnostic delays and worse outcomes.

NOT Open Access | Pandemic's fallout on malaria control appears limited so far

August 24, 2020 - 15:06 -- NOT Open Access
Author(s): 
Roberts L
Reference: 
Science. 2020 Aug 21;369(6506):892

Back in March when COVID-19 hit, some scientists worried malaria cases and deaths might soar. African countries went on lockdown; worried about mass gatherings, they suspended campaigns to distribute mosquito-fighting bed nets. Fears abounded that with clinics overwhelmed by COVID-19, patients would be unable to get treatment for malaria.

Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis

August 24, 2020 - 13:13 -- Open Access
Author(s): 
Kumar N, Awasthi A, Kumari A, Sood D, Jain P, Singh T, Sharma N, Grover A, Chandra R
Reference: 
J Biomol Struct Dyn. 2020 Aug 20:1-16

Coronavirus pandemic has caused a vast number of deaths worldwide. Thus creating an urgent need to develop effective counteragents against novel coronavirus disease (COVID-19). Many antiviral drugs have been repurposed for treatment but implicated minimal recovery, which further advanced the need for clearer insights and innovation to derive effective therapeutics. Strategically, Noscapine, an approved antitussive drug with positive effects on lung linings may show favorable outcomes synergistically with antiviral drugs in trials.

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

August 19, 2020 - 09:15 -- Open Access
Author(s): 
Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M, Andreani J, Fonta I, Mosnier J, Rolland C, Hutter S, La Scola B, Pradines B
Reference: 
Int J Infect Dis. 2020 Aug 14:S1201-9712(20)30661-5

At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with particular hotspot in Southern Europe and America. Many studies predicted a similar epidemic in Africa as that currently seen in Europe and the United States of America. However, reported data do not confirm these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and more particularly artemisinin-based combination therapy (ACT).

Pages

Subscribe to RSS - Covid-19